Comparison of ophthalmic surgery rates in teprotumumab-treated vs. teprotumumab-untreated thyroid eye disease patients

Taylor J. Linaburg¹; Tejus Pradeep¹; Brian Rinelli¹; Yuanyuan Chen¹; Yineng Chen²; Gui-Shuang Ying²; César A. Briceño¹; Madhura Tamhankar¹

DOI: 10.5935/0004-2749.2024-0319

1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, United States of America
2. Department of Ophthalmology, Center for Preventive Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States of America

Corresponding author

Taylor J. Linaburg, MD
E-mail: Taylor. [email protected]

Declaration of Interest Statement: MT serves as a consultant and speaker for Amgen and Viridian. CAB is a consultant for Horizon Therapeutics and Roche/ Genentech. The remaining authors report no conflicts of interest.

Print PDF English

How to cite this article:

Linaburg TJ, Pradeep T, Rinelli B, Chen Y, Chen Y, Ying G, et al. Comparison of ophthalmic surgery rates in teprotumumab-treated vs. teprotumumab-untreated thyroid eye disease patients. Arq. Bras. Oftalmol. 2025;88(5):. 10.5935/0004-2749.2024-0319

Export citation